Last updated on November 2019

A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer


Brief description of study

The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.

Clinical Study Identifier: NCT03898791

Find a site near you

Start Over